1.265

1.56% -0.02

After Hours: 1.26 -0.005 -0.40%

Alzamend Neuro Inc (ALZN)

Overview News Price History Financials Why ALZN Down? Discussions Forecast Stock Split

Alzamend Neuro Inc stock is traded at $1.265, with a volume of 120.54K. It is down -1.56% in the last 24 hours and down -21.43% over the past month. Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Previous Close:

$1.285

Open:

$1.27

24h Volume:

120.54K

Relative Volume:

0.42

Market Cap:

$5.75M

Revenue:

Net Income/Loss:

$-12.40M

P/E Ratio:

-7.9063

EPS:

-0.16

Net Cash Flow:

$-9.08M

1W Performance:

-3.44%

1M Performance:

-21.43%

6M Performance:

-78.92%

1Y Performance:

-87.35%

1-Day Range:

$1.26

$1.30

1-Week Range:

$1.26

$1.36

52-Week Range:

$1.25

$15.06

Alzamend Neuro Inc Stock (ALZN) Company Profile

Name

Alzamend Neuro Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

844-722-6333

Address

3500 LENOX RD. NE, ATLANTA

Employee

Twitter

Next Earnings Date

2024-09-12

Latest SEC Filings

ALZN's Discussions on Twitter

Compare ALZN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALZN Alzamend Neuro Inc	1.265	5.75M	0	-12.40M	-9.08M	-0.16
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-01-21	Initiated	Ascendiant Capital Markets	Buy

Alzamend Neuro Inc Stock (ALZN) Latest News

Nov 19, 2024

Alzamend reports promising results for brain-targeted lithium therapy - Investing.com India

Nov 19, 2024

Alzamend's AL001 Shows Superior Brain Penetration vs Traditional Lithium in Key Study | ALZN Stock News - StockTitan

Nov 19, 2024

EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential - Yahoo Finance

Nov 19, 2024

Nov 15, 2024

Alzamend Neuro stock hits 52-week low at $1.39 amid sharp decline - Investing.com

Nov 15, 2024

Oct 24, 2024

Alzamend Neuro sets trial dosage for AL001 lithium therapy - Alzheimer's News Today

Oct 24, 2024

Oct 17, 2024

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s - BioSpace

Oct 17, 2024

Oct 16, 2024

Alzamend Neuro advances Alzheimer's treatment with new lithium dose - Investing.com

Oct 16, 2024

Alzamend Neuro advances Alzheimer's treatment with new lithium dose By Investing.com - Investing.com South Africa

Oct 16, 2024

EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's - Yahoo Finance

Oct 16, 2024

Oct 15, 2024